These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39033425)

  • 1. Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.
    Federici AB; Santoro RC; Santoro C; Pieri L; Santi RM; Barillari G; Borchiellini A; Tosetto A; Zanon E; De Cristofaro R; Mairal E; Mir R
    Clin Appl Thromb Hemost; 2024; 30():10760296241264541. PubMed ID: 39033425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Efficacy and Safety of Fanhdi
    Jiménez-Yuste V; Alvarez-Román MT; Palomo Bravo Á; Galmes BJ; Nieto Hernández MDM; Benítez Hidalgo O; Marzo Alonso C; Pérez González NF; Coll J; Núñez R; Carrasco M; García Candel F; Gonzalez-Porras JR; Hernández García C; Varó Castro MJ; Mir R
    Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.
    Federici AB; Barillari G; Zanon E; Mazzucconi MG; Musso R; Targhetta R; Mannucci PM
    Haemophilia; 2010 Jan; 16(1):101-10. PubMed ID: 19811543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
    Federici AB; Bucciarelli P; Castaman G; Baronciani L; Canciani MT; Mazzucconi MG; Morfini M; Rocino A; Schiavoni M; Oliovecchio E; Iorio A; Mannucci PM
    Semin Thromb Hemost; 2011 Jul; 37(5):511-21. PubMed ID: 22102194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
    Federici AB
    Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
    Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
    Peyvandi F; Castaman G; Gresele P; De Cristofaro R; Schinco P; Bertomoro A; Morfini M; Gamba G; Barillari G; Jiménez-Yuste V; Königs C; Iorio A; Federici AB
    Blood Transfus; 2019 Sep; 17(5):391-398. PubMed ID: 30747707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
    Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
    Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.
    Federici AB; Castaman G; Franchini M; Morfini M; Zanon E; Coppola A; Tagliaferri A; Boeri E; Mazzucconi MG; Rossetti G; Mannucci PM
    Haematologica; 2007 Jul; 92(7):944-51. PubMed ID: 17606445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.
    Castaman G; Coppola A; Zanon E; Boeri E; Musso M; Siragusa S; Federici AB; Mancuso G; Barillari G; Biasoli C; Feola G; Franchini M; Moratelli S; Gamba G; Schinco P; Valdrè L; Dragani A; Mazzucconi G; Tagliaferri A; Morfini M
    Haemophilia; 2013 Jan; 19(1):82-8. PubMed ID: 22957493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of hFVIII/VWF concentrate (Voncento
    Rugeri L; d'Oiron R; Harroche A; Proulle V; Mourey G; De Raucourt E; Desprez D; Baikian NI; Petesch BP; Borel-Derlon A; Combe S; Frotscher B; Hassoun A; Catovic H; Bracquart D; Trossaërt M
    Blood Transfus; 2021 Mar; 19(2):152-157. PubMed ID: 33263522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results.
    Bello IF; Yuste VJ; Molina MQ; Navarro FH
    Haemophilia; 2007 Dec; 13 Suppl 5():25-32. PubMed ID: 18078394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of current perioperative management with Haemate
    Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a VWF/FVIII concentrate (wilate
    Srivastava A; Serban M; Werner S; Schwartz BA; Kessler CM;
    Haemophilia; 2017 Mar; 23(2):264-272. PubMed ID: 28026130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
    Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
    Borel-Derlon A; Federici AB; Roussel-Robert V; Goudemand J; Lee CA; Scharrer I; Rothschild C; Berntorp E; Henriet C; Tellier Z; Bridey F; Mannucci PM
    J Thromb Haemost; 2007 Jun; 5(6):1115-24. PubMed ID: 17403090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.